Search results
Showing 211 to 225 of 551 results for weight management
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..
Dementia. Patient decision aid on enteral (tube) feeding for people living with severe dementia
Decision aid for Dementia: assessment, management and support for people living with dementia and their carers c NICE 2018. All rights...
Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.
Obesity in adults: prevention and lifestyle weight management programmes (QS111)
This quality standard has been updated and replaced by NICE quality standard 212.
Weight management: lifestyle services for overweight or obese adults (PH53)
This guideline has been updated and replaced by NICE guideline NG246.
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2: CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard
Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (HTG652)
Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.
View recommendations for HTG652Show all sections
Evidence-based recommendations on tisotumab vedotin (Tivdak) for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults.
Show all sections
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant (HTG732)
Evidence-based recommendations on direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. This involves inserting a metal implant through the skin and into the centre of the bone of the stump and attaching a prosthetic limb to it.
View recommendations for HTG732Show all sections
This quality standard covers diagnosing and managing menopause in women, trans men and non-binary people registered female at birth, including those who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.
View quality statements for QS143Show all sections
Sections for QS143
- Quality statements
- Quality statement 1: Diagnosing perimenopause and menopause
- Quality statement 2: Diagnosing premature ovarian insufficiency
- Quality statement 3: Managing premature ovarian insufficiency
- Quality statement 4: Reviewing treatments for menopause-associated symptoms
- Quality statement 5: Information before treatment likely to cause menopause
- Update information
- About this quality standard